Holen Sie sich die Stockscreener-App
32.10
0.50%
0.16
Handel nachbörslich:
32.30
0.20
+0.62%
Schlusskurs vom Vortag:
$31.94
Offen:
$32.1
24-Stunden-Volumen:
2.79M
Relative Volume:
0.79
Marktkapitalisierung:
$3.61B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-34.52
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
+4.56%
1M Leistung:
+23.41%
6M Leistung:
-5.73%
1J Leistung:
-37.92%
1-Tages-Spanne:
$31.63
$32.59
1-Wochen-Bereich:
$30.67
$33.61
52-Wochen-Spanne:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
32.10 | 3.45B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
What drives Viking Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com
What analysts say about Viking Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Viking Therapeutics (VKTX) Set to Release Q2 Earnings Results - GuruFocus
Viking Therapeutics Inc. Stock Analysis and ForecastAccelerated investment success - jammulinksnews.com
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - The Globe and Mail
Viking Therapeutics to Report Q2 2025 Financial Results on July 23, 2025 - AInvest
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - MSN
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
Viking Therapeutics VKTX 2025Q2 Earnings Preview Upside Potential Driven by Analyst Price Targets - AInvest
Is Viking Therapeutics Inc. a good long term investmentBreakthrough stock performance - PrintWeekIndia
Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results - MSN
(VKTX) On The My Stocks Page - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Soars 3.40% on Bullish Analyst Sentiment - AInvest
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know - MSN
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 - 富途牛牛
Viking Therapeutics to Report Financial Results for Second Quart - GuruFocus
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 | VKTX Stock News - GuruFocus
Viking Therapeutics Q2 Earnings: Novel Metabolic Drug Developer to Reveal Latest Financial Results - Stock Titan
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - Insider Monkey
Why Viking Therapeutics Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - beatles.ru
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - MSN
VKTX August 29th Options Begin Trading - Nasdaq
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies - Seeking Alpha
This Insider Has Just Sold Shares In Viking Therapeutics - simplywall.st
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - MSN
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity - The Motley Fool
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts (NASDAQ:VKTX) - Seeking Alpha
August 22nd Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
Viking Therapeutics, Inc.(NasdaqCM: VKTX) added to Russell Midcap Value Index - MarketScreener
Viking Therapeutics' Russell Move: A Biotech Breakout on the Horizon? - AInvest
Viking Therapeutics (VKTX) Opinions on Phase 3 Obesity Trial Launch - Quiver Quantitative
Why This Weight Loss Drug Company's Stock Surged Today - AOL.com
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):